Comparative trials of anti-VEGFs show no statistically significant differences, speaker says

NEW ORLEANS — Comparative studies such as CATT, IVAN, MANTA, GEFAL, BRAMD and LUCAS have shown no clinically significant differences between ranibizumab and bevacizumab, a speaker said here. “There are no statistical differences between these small percentages. People keep trying to make it significant. It’s probably noise,” Daniel F. Martin, MD, chairman of the Cole Eye Institute, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.

Full Story →